
The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
GSK Plc (GLAXF), as a healthcare company, researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products.
The company was formerly known as GlaxoSmithKline and changed its name to GSK plc in 2022.
Three key data points gauge GLAXF (or any dividend-paying entity):
(1) Price
(2) Dividends
(3) Returns
Those three keys also indicate if any company has made, is making, and will make money.
GLAXF Price
GSK plc’s single share price climbed up $0.90 (or about 20%) from $19.05 to $25.70 in the past year, per Tuesday’s morning market report.
No analysts cover the stock. So a one-year price target is not available. However, three years of price history show an average $2.90 annual price gain, which I’ll use to calculate returns after I discuss dividends.
GLAXF Dividends
GSK plc has paid quarterly dividends since April, 2012. The most recent Q dividend of $0.23 is payable July 9 (to shareholders on record as of May 15), equating to a forward annual payout of $0.92, yielding 3.58%
GLAXF Returns
Putting it all together, as of May 19, a possible gross gain of $3.82 was projected. The $2.90 per share annual gain was added to the $0.92 forward looking annual dividend.
A little over $1000 invested in GLAXF at Tuesday’s $25.70 opening share price would buy 39 shares which multiply the $3.82 gross gain to $148.63 for the coming year, or 14.86%.
My dividend dogcatcher rule is to only buy initial shares of a dividend stock that pay an annual dividend (from $1000 invested) that is more than the cost of one share.
GLAXF’s annual dividend from $1K invested is $35.80. So GLAXF shows a dividend from $1,000 invested about 1.4 times its $25.70 single share price of Tuesday.
The exact track of GLAXF’s future share price and dividend will entirely be determined by market action and company finances.
Remember, the best way to track stock performance and dividend payments is through direct ownership of company shares.




Comments
Log in or sign up to join the conversation.